Gene | Associated with CARDIOFACIOCUTANEOUS SYNDROME in | Link to HGNC | Cytogenetic band | Number of associated diseases | Associated diseases |
---|---|---|---|---|---|
MAP2K2 | ClinVar, OMIM, HUMSAVAR | HGNC link | 19p13.3 | 1 | PS115150 |
MAP2K1 | ClinVar, OMIM, HUMSAVAR | HGNC link | 15q22.31 | 1 | PS115150 |
BRAF | ClinVar, OMIM, HUMSAVAR | HGNC link | 7q34 | 8 | 605027, PS115150, PS151100, PS155600, 211980, PS188550, PS163950, 114500 |
KRAS | ClinVar, OMIM, HUMSAVAR | HGNC link | 12p12.1 | 14 | 601626, 600268, 137215, 109800, PS163950, 211980, 114480, PS115150, 613659, 163200, 607785, 614470, 162900, 260350 |
Download the disease annotation in CSV format
regulated gene | associated to this disease | # TFs | TFs | # TFs associated with this disease | TFs associated with this disease |
---|---|---|---|---|---|
KRAS | YES | 1 | MYC | 0 |
Gene1 | Gene2 | Direct Interaction | Number of shared interactors | Shared genes in interaction |
---|---|---|---|---|
MAP2K2 | MAP2K1 | Yes | 16 | MAP2K2, WDR83, FLNA, ARAF, MAPK1, MAP2K1, IQGAP1, MAPK3, MAPK8, KSR1, NFE2L2, PDLIM5, RAF1, RPE, BRAF, YWHAB |
MAP2K2 | BRAF | Yes | 9 | MAP2K2, ARAF, MAPK3, MAP2K1, MAPK1, IQGAP1, RAF1, BRAF, YWHAB |
MAP2K2 | KRAS | No | 3 | MAPK1, ARAF, RAF1 |
MAP2K1 | BRAF | Yes | 17 | HSPA1A, HSPA8, NEDD4, ARAF, MAPK1, HRAS, IQGAP1, MAPK3, MAP2K2, KSR1, BRAF, YWHAE, YWHAZ, RAF1, YWHAB, MAP2K1, BRAP |
MAP2K1 | KRAS | No | 5 | BTRC, ELAVL1, MAPK1, ARAF, RAF1 |
BRAF | KRAS | No | 3 | MAPK1, ARAF, RAF1 |
Direct interactions graph
Interactions graph (direct and indirect interactions, when direct are not available)
Gene1 | Gene2 | Direct Interaction | Number of shared interactors | Shared genes in interaction |
---|---|---|---|---|
MAP2K1 | KRAS | Yes | 1 | KRAS |
Direct interactions graph
Interactions graph (direct and indirect interactions, when direct are not available)
Direct interactions graph
Interactions graph (direct and indirect interactions, when direct are not available)
Gene1 | Gene2 | Direct Interaction | Complexes | Number of shared interactors | Shared genes in interaction |
---|---|---|---|---|---|
MAP2K2 | MAP2K1 | Yes | BRAF-MAP2K1-MAP2K2-YWHAE complex | 4 | BRAF, YWHAE, RAF1, KSR1 |
MAP2K2 | BRAF | Yes | KSR1-BRAF-MEK complex | 4 | MAP2K1, YWHAE, RAF1, KSR1 |
MAP2K2 | KRAS | No | - | 1 | RAF1 |
MAP2K1 | BRAF | Yes | KSR1-BRAF-MEK complex | 4 | MAP2K2, YWHAE, KSR1, RAF1 |
MAP2K1 | KRAS | No | - | 1 | RAF1 |
BRAF | KRAS | No | - | 1 | RAF1 |
Direct interactions graph
Interactions graph (direct and indirect interactions, when direct are not available)
Gene1 | Gene2 | Interaction | Number of common interactors | Common genes in interaction |
---|---|---|---|---|
MAP2K1 | BRAF | Yes | 2 | MAP2K1, BRAF |
Direct interactions graph
Interactions graph (direct and indirect interactions, when direct are not available)
KEGG term | KEGG term ID | IC | Number of genes with the same term | Genes |
---|---|---|---|---|
Melanoma | hsa05218 | 6.56 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Bladder cancer | hsa05219 | 7.38 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Natural killer cell mediated cytotoxicity | hsa04650 | 5.53 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
MAPK signaling pathway | hsa04010 | 4.63 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Thyroid cancer | hsa05216 | 7.48 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Glioma | hsa05214 | 6.66 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Prostate cancer | hsa05215 | 6.11 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Long-term potentiation | hsa04720 | 6.64 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Neurotrophin signaling pathway | hsa04722 | 5.78 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
FoxO signaling pathway | hsa04068 | 5.63 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Endometrial cancer | hsa05213 | 6.81 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Renal cell carcinoma | hsa05211 | 6.6 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Proteoglycans in cancer | hsa05205 | 5.02 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Pathways in cancer | hsa05200 | 3.98 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Insulin signaling pathway | hsa04910 | 5.55 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Non-small cell lung cancer | hsa05223 | 6.88 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
ErbB signaling pathway | hsa04012 | 6.15 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Acute myeloid leukemia | hsa05221 | 6.74 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Chronic myeloid leukemia | hsa05220 | 6.48 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Long-term depression | hsa04730 | 6.74 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Regulation of actin cytoskeleton | hsa04810 | 4.9 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Rap1 signaling pathway | hsa04015 | 4.97 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Signaling pathways regulating pluripotency of stem cells | hsa04550 | 5.6 | 3 | MAP2K2, MAP2K1, KRAS |
Pancreatic cancer | hsa05212 | 6.56 | 3 | MAP2K1, BRAF, KRAS |
Colorectal cancer | hsa05210 | 6.52 | 3 | MAP2K1, BRAF, KRAS |
cAMP signaling pathway | hsa04024 | 5.05 | 3 | MAP2K2, MAP2K1, BRAF |
Central carbon metabolism in cancer | hsa05230 | 6.7 | 3 | MAP2K2, MAP2K1, KRAS |
Choline metabolism in cancer | hsa05231 | 6.09 | 3 | MAP2K2, MAP2K1, KRAS |
Serotonergic synapse | hsa04726 | 5.84 | 3 | MAP2K1, BRAF, KRAS |
Chemokine signaling pathway | hsa04062 | 5.19 | 3 | MAP2K1, BRAF, KRAS |
Oxytocin signaling pathway | hsa04921 | 5.4 | 3 | MAP2K2, MAP2K1, KRAS |
Hepatitis B | hsa05161 | 5.52 | 3 | MAP2K2, MAP2K1, KRAS |
Vascular smooth muscle contraction | hsa04270 | 5.74 | 3 | MAP2K2, MAP2K1, BRAF |
Gap junction | hsa04540 | 6.24 | 3 | MAP2K2, MAP2K1, KRAS |
VEGF signaling pathway | hsa04370 | 6.77 | 3 | MAP2K2, MAP2K1, KRAS |
MicroRNAs in cancer | hsa05206 | 5.38 | 3 | MAP2K2, MAP2K1, KRAS |
T cell receptor signaling pathway | hsa04660 | 6.01 | 3 | MAP2K2, MAP2K1, KRAS |
B cell receptor signaling pathway | hsa04662 | 6.52 | 3 | MAP2K2, MAP2K1, KRAS |
Ras signaling pathway | hsa04014 | 4.9 | 3 | MAP2K2, MAP2K1, KRAS |
Melanogenesis | hsa04916 | 5.97 | 3 | MAP2K2, MAP2K1, KRAS |
Prolactin signaling pathway | hsa04917 | 6.6 | 3 | MAP2K2, MAP2K1, KRAS |
Progesterone-mediated oocyte maturation | hsa04914 | 6.18 | 3 | MAP2K1, BRAF, KRAS |
Estrogen signaling pathway | hsa04915 | 6.11 | 3 | MAP2K2, MAP2K1, KRAS |
Thyroid hormone signaling pathway | hsa04919 | 5.82 | 3 | MAP2K2, MAP2K1, KRAS |
PI3K-Akt signaling pathway | hsa04151 | 4.21 | 3 | MAP2K2, MAP2K1, KRAS |
GnRH signaling pathway | hsa04912 | 6.18 | 3 | MAP2K2, MAP2K1, KRAS |
Alcoholism | hsa05034 | 5.59 | 3 | MAP2K1, BRAF, KRAS |
Fc epsilon RI signaling pathway | hsa04664 | 6.6 | 3 | MAP2K2, MAP2K1, KRAS |
cGMP-PKG signaling pathway | hsa04022 | 5.32 | 2 | MAP2K2, MAP2K1 |
Toll-like receptor signaling pathway | hsa04620 | 6.0 | 2 | MAP2K2, MAP2K1 |
Influenza A | hsa05164 | 5.21 | 2 | MAP2K2, MAP2K1 |
Cholinergic synapse | hsa04725 | 5.88 | 2 | MAP2K1, KRAS |
Prion diseases | hsa05020 | 7.48 | 2 | MAP2K2, MAP2K1 |
Focal adhesion | hsa04510 | 4.92 | 2 | MAP2K1, BRAF |
HIF-1 signaling pathway | hsa04066 | 5.9 | 2 | MAP2K2, MAP2K1 |
Hepatitis C | hsa05160 | 5.68 | 2 | BRAF, KRAS |
Dorso-ventral axis formation | hsa04320 | 8.01 | 2 | MAP2K1, KRAS |
REACTOME term | REACTOME term ID | IC | Number of genes with the same term | Genes |
---|---|---|---|---|
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 4.85 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Immune System | R-HSA-168256 | 2.37 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 4.26 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
NCAM signaling for neurite out-growth | R-HSA-375165 | 4.9 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Signaling by Interleukins | R-HSA-449147 | 4.71 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
GRB2 events in ERBB2 signaling | R-HSA-1963640 | 5.15 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Frs2-mediated activation | R-HSA-170968 | 5.12 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
MAP2K and MAPK activation | R-HSA-5674135 | 7.66 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Cytokine Signaling in Immune system | R-HSA-1280215 | 3.74 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
IGF1R signaling cascade | R-HSA-2428924 | 4.85 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Downstream signal transduction | R-HSA-186763 | 4.65 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
IRS-related events triggered by IGF1R | R-HSA-2428928 | 4.85 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Signaling by ERBB4 | R-HSA-1236394 | 4.7 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Signaling by Insulin receptor | R-HSA-74752 | 4.73 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
RAF activation | R-HSA-5673000 | 8.34 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
RAF/MAP kinase cascade | R-HSA-5673001 | 5.15 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Downstream signaling of activated FGFR1 | R-HSA-5654687 | 4.71 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
MAPK family signaling cascades | R-HSA-5683057 | 4.89 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Signaling by Leptin | R-HSA-2586552 | 5.1 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Signaling by VEGF | R-HSA-194138 | 4.66 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Signalling to p38 via RIT and RIN | R-HSA-187706 | 5.12 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
FCERI mediated MAPK activation | R-HSA-2871796 | 4.32 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
IRS-mediated signalling | R-HSA-112399 | 4.87 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
FRS-mediated FGFR2 signaling | R-HSA-5654700 | 5.14 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
SOS-mediated signalling | R-HSA-112412 | 5.15 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
FRS-mediated FGFR3 signaling | R-HSA-5654706 | 5.14 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Developmental Biology | R-HSA-1266738 | 3.48 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Downstream signaling of activated FGFR3 | R-HSA-5654708 | 4.71 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Insulin receptor signalling cascade | R-HSA-74751 | 4.85 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Signaling by FGFR4 | R-HSA-5654743 | 4.69 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Signaling by FGFR3 | R-HSA-5654741 | 4.69 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 4.7 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Signaling by FGFR | R-HSA-190236 | 4.67 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 4.03 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Interleukin-2 signaling | R-HSA-451927 | 5.05 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
MAPK1/MAPK3 signaling | R-HSA-5684996 | 5.11 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Interleukin receptor SHC signaling | R-HSA-912526 | 5.09 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Innate Immune System | R-HSA-168249 | 3.17 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Signaling by SCF-KIT | R-HSA-1433557 | 4.73 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
SHC1 events in ERBB2 signaling | R-HSA-1250196 | 5.15 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Signalling to ERKs | R-HSA-187687 | 5.04 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Signaling by PDGF | R-HSA-186797 | 4.53 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Signalling to RAS | R-HSA-167044 | 5.08 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
DAP12 signaling | R-HSA-2424491 | 4.64 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Interleukin-3, 5 and GM-CSF signaling | R-HSA-512988 | 4.99 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Downstream signaling of activated FGFR2 | R-HSA-5654696 | 4.71 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
SHC1 events in ERBB4 signaling | R-HSA-1250347 | 5.15 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
SHC1 events in EGFR signaling | R-HSA-180336 | 5.15 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
NGF signalling via TRKA from the plasma membrane | R-HSA-187037 | 4.51 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
FRS-mediated FGFR1 signaling | R-HSA-5654693 | 5.14 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Prolonged ERK activation events | R-HSA-169893 | 5.11 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Negative regulation of MAPK pathway | R-HSA-5675221 | 7.66 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
FRS-mediated FGFR4 signaling | R-HSA-5654712 | 5.14 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Signalling by NGF | R-HSA-166520 | 4.23 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Signaling by GPCR | R-HSA-372790 | 2.68 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Signaling by FGFR2 | R-HSA-5654738 | 4.68 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
GRB2 events in EGFR signaling | R-HSA-179812 | 5.15 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Signaling by FGFR1 | R-HSA-5654736 | 4.69 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Signaling by EGFR | R-HSA-177929 | 4.59 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
ARMS-mediated activation | R-HSA-170984 | 5.12 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
DAP12 interactions | R-HSA-2172127 | 4.56 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Downstream signaling of activated FGFR4 | R-HSA-5654716 | 4.71 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Signaling by ERBB2 | R-HSA-1227986 | 4.66 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Axon guidance | R-HSA-422475 | 3.93 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
VEGFR2 mediated cell proliferation | R-HSA-5218921 | 5.07 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Signal Transduction | R-HSA-162582 | 1.78 | 4 | MAP2K2, MAP2K1, KRAS, BRAF |
Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 10.4 | 3 | MAP2K2, MAP2K1, BRAF |
Disease | R-HSA-1643685 | 3.33 | 3 | MAP2K2, MAP2K1, KRAS |
Infectious disease | R-HSA-5663205 | 4.47 | 2 | MAP2K2, MAP2K1 |
Signal transduction by L1 | R-HSA-445144 | 8.59 | 2 | MAP2K2, MAP2K1 |
L1CAM interactions | R-HSA-373760 | 6.19 | 2 | MAP2K2, MAP2K1 |
Uptake and actions of bacterial toxins | R-HSA-5339562 | 8.28 | 2 | MAP2K2, MAP2K1 |
Uptake and function of anthrax toxins | R-HSA-5210891 | 9.66 | 2 | MAP2K2, MAP2K1 |
RAF-independent MAPK1/3 activation | R-HSA-112409 | 8.46 | 2 | MAP2K2, MAP2K1 |
Term | New enriched term | IC | P value | Genes |
---|---|---|---|---|
anchoring junction (GO:0070161) | - | 3.61 | 0.002 | MAP2K2, MAP2K1, KRAS, BRAF |
adherens junction (GO:0005912) | - | 3.66 | 0.001 | MAP2K2, MAP2K1, KRAS, BRAF |
late endosome (GO:0005770) | - | 4.85 | 0.013 | MAP2K2, MAP2K1 |
mitochondrion (GO:0005739) | - | 2.42 | 0.001 | MAP2K2, MAP2K1, KRAS, BRAF |
cell cortex (GO:0005938) | NEW | 4.78 | 0.014 | MAP2K2, MAP2K1 |
cell-substrate adherens junction (GO:0005924) | - | 3.83 | 0.001 | MAP2K2, MAP2K1, KRAS, BRAF |
focal adhesion (GO:0005925) | - | 3.83 | 0.002 | MAP2K2, MAP2K1, KRAS, BRAF |
early endosome (GO:0005769) | - | 4.34 | 0.008 | MAP2K2, MAP2K1, KRAS |
cell junction (GO:0030054) | - | 2.75 | 0.042 | MAP2K2, MAP2K1, KRAS |
cell-substrate junction (GO:0030055) | - | 3.82 | 0.002 | MAP2K2, MAP2K1, KRAS, BRAF |